10:46:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 Ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2023-12-15 17:53:00

Bergen, Norway, December 15th, 2023, Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), informs that the formal relationship with the Company’s Chief Scientific Officer (CSO) will be adjusted from an consultancy agreement to an employment agreement.

Since 2013, Prof. Dr. Dr. Med. Andreas Pfützner has been engaged in the role of CSO in Lifecare. The professional relationship has so far been based on a management-for-hire contract through his wholly owned and controlled company Islay Ventures GmbH (“IV”). Aligned with Lifecare's long term strategy, Prof. Pfützner will now act as the Company's CSO based on an employment relationship, with effect from January 1st, 2024.

Prof. Pfützner is a highly recognized diabetologist and runs a diabetes research institute co-located with Lifecare Laboratory GmbH in Mainz, Germany. Prof. Pfützner has more than 30 years of experience with development of medical devices and products primarily related to diabetes and diabetes technology. He is a teaching professor at DTMD University in Luxembourg and the University of Bingen, Germany.

For many years, Prof. Pfützner has been an attractive and sought-after speaker at highly recognized and professionally relevant arenas. This naturally has positive ripple effects for Lifecare and has also opened the doors to academic circles, which have been of great benefit to the Company.

- Prof. Pützner has had a very important position at Lifecare for a decade and will permanently continue to do so. While the formal adjustment into an employment agreement implies no practical changes in the daily business of the Company and our projects, it indicates an even stronger commitment of the CSO and we are very pleased to conclude the formal connection into an employment relationship. This adjustment is in line with Lifecare’s long term strategy and not least secure the base of essential key personnel, says Joacim Holter, Lifecare CEO.